Literature DB >> 16537611

Effects of type I interferons on Friend retrovirus infection.

Nicole Gerlach1, Simone Schimmer, Siegfried Weiss, Ulrich Kalinke, Ulf Dittmer.   

Abstract

The type I interferon (IFN) response plays an important role in the control of many viral infections. However, since there is no rodent animal model for human immunodeficiency virus, the antiviral effect of IFN-alpha and IFN-beta in retroviral infections is not well characterized. In the current study we have used the Friend virus (FV) model to determine the activity of type I interferons against a murine retrovirus. After FV infection of mice, IFN-alpha and IFN-beta could be measured between 12 and 48 h in the serum. The important role of type I IFN in the early immune defense against FV became evident when mice deficient in IFN type I receptor (IFNAR(-/-)) or IFN-beta (IFN-beta(-/-)) were infected. The levels of FV infection in plasma and in spleen were higher in both strains of knockout mice than in C57BL/6 wild-type mice. This difference was induced by an antiviral effect of IFN-alpha and IFN-beta and was most likely mediated by antiviral enzymes as well as by an effect of these IFNs on T-cell responses. Interestingly, the lack of IFNAR and IFN-beta enhanced viral loads during acute and chronic FV infection. Exogenous IFN-alpha could be used therapeutically to reduce FV replication during acute but not chronic infection. These findings indicate that type I IFN plays an important role in the immediate antiviral defense against Friend retrovirus infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16537611      PMCID: PMC1440373          DOI: 10.1128/JVI.80.7.3438-3444.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Friend virus replication in normal and immunosuppressed C57BL/6 mice.

Authors:  H C Van der Gaag; A A Axelrad
Journal:  Virology       Date:  1990-08       Impact factor: 3.616

2.  Role of interleukin-4 (IL-4), IL-12, and gamma interferon in primary and vaccine-primed immune responses to Friend retrovirus infection.

Authors:  U Dittmer; K E Peterson; R Messer; I M Stromnes; B Race; K J Hasenkrug
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Activation of erythropoietin receptors by Friend viral gp55 and by erythropoietin and down-modulation by the murine Fv-2r resistance gene.

Authors:  M E Hoatlin; S L Kozak; F Lilly; A Chakraborti; C A Kozak; D Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

4.  Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor.

Authors:  J P Li; A D D'Andrea; H F Lodish; D Baltimore
Journal:  Nature       Date:  1990-02-22       Impact factor: 49.962

5.  Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection.

Authors:  M von Sydow; A Sönnerborg; H Gaines; O Strannegård
Journal:  AIDS Res Hum Retroviruses       Date:  1991-04       Impact factor: 2.205

6.  Immunomodulator effects on the Friend virus infection in genetically defined mice.

Authors:  R W Sidwell; J D Morrey; K M Okleberry; R A Burger; R P Warren
Journal:  Ann N Y Acad Sci       Date:  1993-06-23       Impact factor: 5.691

7.  Interferon alpha-mediated inhibition of human immunodeficiency virus type 1 provirus synthesis in T-cells.

Authors:  Y Shirazi; P M Pitha
Journal:  Virology       Date:  1993-03       Impact factor: 3.616

8.  Alpha interferon inhibits early stages of the human immunodeficiency virus type 1 replication cycle.

Authors:  Y Shirazi; P M Pitha
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

9.  Functional role of type I and type II interferons in antiviral defense.

Authors:  U Müller; U Steinhoff; L F Reis; S Hemmi; J Pavlovic; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

10.  Effect of the combination of interferon-alpha and stavudine on Friend virus infections in (B10.A x A.By)F1 mice.

Authors:  R W Sidwell; R P Warren; K Okleberry; R A Burger; J D Morrey
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

View more
  40 in total

Review 1.  HIV-1 Infection and Type 1 Interferon: Navigating Through Uncertain Waters.

Authors:  Sho Sugawara; David L Thomas; Ashwin Balagopal
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-15       Impact factor: 2.205

2.  Innate immune sensing of retroviral infection via Toll-like receptor 7 occurs upon viral entry.

Authors:  Melissa Kane; Laure K Case; Christine Wang; Leonid Yurkovetskiy; Stanislav Dikiy; Tatyana V Golovkina
Journal:  Immunity       Date:  2011-06-30       Impact factor: 31.745

3.  Systemic Expression of a Viral RdRP Protects against Retrovirus Infection and Disease.

Authors:  Caitlin M Miller; Bradley S Barrett; Jianfang Chen; James H Morrison; Caleb Radomile; Mario L Santiago; Eric M Poeschla
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

4.  Type I Interferons Act Directly on Nociceptors to Produce Pain Sensitization: Implications for Viral Infection-Induced Pain.

Authors:  Paulino Barragán-Iglesias; Úrzula Franco-Enzástiga; Vivekanand Jeevakumar; Stephanie Shiers; Andi Wangzhou; Vinicio Granados-Soto; Zachary T Campbell; Gregory Dussor; Theodore J Price
Journal:  J Neurosci       Date:  2020-04-03       Impact factor: 6.167

5.  Toll-like receptor 7 inhibits early acute retroviral infection through rapid lymphocyte responses.

Authors:  Edward P Browne
Journal:  J Virol       Date:  2013-04-24       Impact factor: 5.103

6.  SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism.

Authors:  Matthew B Frieman; Jun Chen; Thomas E Morrison; Alan Whitmore; William Funkhouser; Jerrold M Ward; Elaine W Lamirande; Anjeanette Roberts; Mark Heise; Kanta Subbarao; Ralph S Baric
Journal:  PLoS Pathog       Date:  2010-04-08       Impact factor: 6.823

7.  Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity.

Authors:  Amy H Lin; Cindy Burrascano; Par L Pettersson; Carlos E Ibañez; Harry E Gruber; Douglas J Jolly
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

8.  IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3.

Authors:  Michael S Harper; Bradley S Barrett; Diana S Smith; Sam X Li; Kathrin Gibbert; Ulf Dittmer; Kim J Hasenkrug; Mario L Santiago
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

Review 9.  Humoral immunity in the Friend retrovirus infection model.

Authors:  Kalani Halemano; Michael S Harper; Kejun Guo; Sam X Li; Karl J Heilman; Bradley S Barrett; Mario L Santiago
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

10.  Differential requirements of cellular and humoral immune responses for Fv2-associated resistance to erythroleukemia and for regulation of retrovirus-induced myeloid leukemia development.

Authors:  Sachiyo Tsuji-Kawahara; Hiroyuki Kawabata; Hideaki Matsukuma; Saori Kinoshita; Tomomi Chikaishi; Mayumi Sakamoto; Yuri Kawasaki; Masaaki Miyazawa
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.